Eli Lilly's (LLY +0.2%) dulaglutide treatment for type 2 diabetes performs well in three Phase...


Eli Lilly's (LLY +0.2%) dulaglutide treatment for type 2 diabetes performs well in three Phase III studies, meeting the primary endpoints as measured by lower levels of hemoglobin A1c, which helps indicate blood sugar control. The most frequently reported side-effects were gastrointestinal-related. Other studies of dulaglutide are taking place, with two due to conclude in the next few months. (PR)

From other sites
Comments (2)
  • Bible1
    , contributor
    Comments (3) | Send Message
     
    It is important to add to this article, that lifestyle changes are still required for any medication to work effectively and that there are no "magic bullets" that allow diabetic patients to eat whatever they want without strict guidelines, and proper exercise. :-)
    22 Oct 2012, 03:49 PM Reply Like
  • Bible1
    , contributor
    Comments (3) | Send Message
     
    My wife is a fantistic chef, and my daughter has completed culinary school intending to have her own restaurant.
    22 Oct 2012, 03:50 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs